Abstract:Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Growing evidence from clinical investigations has shown that increased serum levels of YKL-40 are correlated with short survival and metastasis in a broad type of human cancers. These data suggest that YKL-40 in the blood may present a powerful tool for cancer diagnosis and prognosis. However, pathological activity of YKL-40 in cancer development is poorly understood. Here, we explored a functional role for YKL-40 in vasculature development of human cancer. In a survey of twenty cases of breast ductal carcinoma in situ (DCIS) and thirty-eight cases of infiltrating ductal carcinoma (IDC), we found that expression levels of YKL-40 in specimens from DCIS were barely detectable, but different levels of YKL-40 were present in IDC. Nine out of thirty-eight IDC cases showed high levels of YKL-40 and nine cases displayed medium levels of YKL-40, whereas the rest twenty cases were low or negative. Interestingly, in an analysis of vasculature formation in these IDC samples, we found that different blood vessel densities significantly correlated with different degrees of YKL-40 expression. To test this possible angiogenic activity of YKL-40 in tumor development, we utilized angiogenic xenograft models by subcutaneous injection of SCID/Beige mice with a brain tumor line U87 cells which express strong endogenous YKL-40 and U87 cells with siRNA knockdown of YKL-40. siRNA knockdown of YKL-40 notably suppressed tumor angiogenesis and tumor development relative to high levels of YKL-40 expressed in control U87 cells. Further, to dissect cellular and molecular mechanisms underlying YKL-40-induced tumor angiogenesis, we treated human microvascular endothelial cells with YKL-40 and found that YKL-40 was capable of binding to heparan sulfate on ectodomain of membrane receptor syndecan-1 (S1). The activated S1 prompted its interaction with adjacent receptor integrin αvβ3, leading to activation of intracellular cascades including phosphorylation of focal adhesion kinase and MAP kinase. A series of individual signaling inhibitors blocked YKL-40-induced angiogenesis in vitro. Collectively, these data strongly suggest that YKL-40 expressed in cancer activates vascular endothelial cell angiogenesis to promote tumor development. These findings may hold promise for developing novel therapeutic agents targeting YKL-40, a cancer biomarker that is overexpressed in a wide range of human cancers. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1732.

YKL-40 acts as an angiogenic factor to promote tumor angiogenesis

YKL-40, a Secreted Glycoprotein, Promotes Tumor Angiogenesis

Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma.

YKL-40: a Potential Biomarker and Therapeutic Target for Breast Cancer Diagnosis and Therapy

Elevated Expression Of Ykl-40, A Cancer Biomarker, Is Associated With Tumor Angiogenesis

Abstract 4620: A YKL-40-neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers

YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models

Tumor-derived Mural-Like Cells Coordinate with Endothelial Cells: Role of YKL-40 in Mural Cell-Mediated Angiogenesis.

Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis

Functional analysis of the short splicing variant encoded by CHI3L1/YKL-40 in glioblastoma

Interleukin-6 Induced by YAP in Hepatocellular Carcinoma Cells Recruits Tumor-Associated Macrophages

A Heparin Binding Motif Rich in Arginine and Lysine is the Functional Domain of YKL-40.

Overexpression of YKL-40 is an Independent Prognostic Marker in Gastric Cancer.

YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer

YKL-39 is an independent prognostic factor in gastric adenocarcinoma and is associated with tumor-associated macrophage infiltration and angiogenesis

The Role of Chitinase-3-like Protein-1 (YKL40) in the Therapy of Cancer and Other Chronic-Inflammation-Related Diseases

Knockdown of YKL‐40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer

Breast Cancer Expression of Ykl-40 Correlates with Tumour Grade, Poor Differentiation, and Other Cancer Markers

Relationship Between YKL-40 and Respiratory Diseases

YKL-40 Promotes the Progress of Atherosclerosis Independent of Lipid Metabolism in Apolipoprotein E−/− Mice Fed a High-Fat Diet

YKL-40: a potential biomarker for osteoarthritis.